

IMSRESEARCH (IMS LifeCycle, R&D Focus)

Subject Coverage	<ul style="list-style-type: none"> • All phases of drug development worldwide • Biotechnological products • New formulations 			
File Type	Substance			
Features	Thesaurus	None	Learning Database	<input type="checkbox"/>
	Alerts (SDIs)	Not available	Page Images	<input type="checkbox"/>
	CAS Registry Number® Identifiers	<input checked="" type="checkbox"/>	SLART	<input checked="" type="checkbox"/>
	Keep & Share	<input checked="" type="checkbox"/>	Structures	<input type="checkbox"/>
Record Content	<ul style="list-style-type: none"> • Substance information • CAS Registry Number and Chemical Name • Structures • Pharmacology • Development and licensing status worldwide • Scientific and commercial summaries • Abstracts of significant scientific papers 			
File Size	49,767 records (01/2023)			
Coverage	1977 – 01/2023			
Updates	Static File			
Language	English			
Database Producer	IQVIA 210 Pentonville Road London N1 9JY United Kingdom Phone: (+44) 020 3075 5888 Email: info@uk.imshealth.com Web: http://www.imshealth.com			
Sources	Information is gathered from direct reports from companies on their research and development, conferences, patent and journal literature, and attendance at symposia on medical, clinical, and research subjects.			
User Aids	<ul style="list-style-type: none"> • Anatomical Therapeutic Classification Codes (available from the producer) • Online Helps (HELP DIRECTORY lists all help messages available) • STNGUIDE 			
Clusters	<ul style="list-style-type: none"> • BIOSCIENCE • CASRNS • PHARMACOLOGY STN Database Clusters Information.			
Pricing	Enter HELP COST at an arrow prompt (=>).			

Search and Display Field Codes

Fields that allow left truncation (/BI, /CNS) are indicated by an asterisk (*).

Search Field Name	Search Code	Search Examples	Display Codes
Basic Index* (contains single words from text (TX), chemical name (CN), classification code (CC), controlled term (CT), revision note (RNTE), reference (RE), latest information (LI), company name (CO), patent assignee (PA), development status (DSTA), geographic terms (GT), launch country (LNC) fields, as well as CAS Registry Numbers)	None (or /BI)	S BETA BLOCKER# S JANSSEN S JAPAN (L) REGISTERED S 61337-67-5 S ?CLASS?	CC, CN, CO, CT, DSTA, LI, LNC, RE, RN, RNTE, TX
Accession Number	/AN	S 93:234/AN S 1998:234/AN	AN
Availability for Licensing	/AV	S WORLDWIDE/AV	DSTA
Chemical Name (contains chemical name, generic name, reference, laboratory code, and trade name)	/CN	S NEBIVOLOL/CN	CN, RE, TN
Chemical Name Segment *	/CNS	S ?METHYLENE?/CNS	CN, TN
Classification Code (1,2) (code and text)	/CC	S CNS DRUGS/CC S C7A/CC S C/CC	CC
Company Name (contains companies, originators, licensees, licensors, patent assignees, corporations, nationality, and region) (1)	/CO	S (LICENSEE(L)BERLEX)/CO S HOECHST ROUSSEL/CO	CO
Controlled Term (contains indication and pharmacology (action))	/CT	S MULTIPLE SCLEROSIS/CT S BIOTECHNOLOGY/CT	CT
Development Status (contains status, stage, region, and indication)	/DSTA	S (REGISTERED (L) UNITED STATES)/DSTA S (PHASE III (L) ALZHEIMER DISEASE)/DSTA	DSTA
Entry Date (3)	/ED	S L1 AND ED>20010100	ED
Field Availability (code and text)	/FA	S RN/FA S PATENT ASSIGNEE/FA	FA
Geographic Term (country name and ISO code)	/GT	S UK/GT	CO, DSTA
Highest Development Phase	/HDP	S PRECLINICAL/HDP	DSTA, HDP
Journal Title (4)	/JT	S R&D FOCUS/JT	JT, SO
Not Available for Licensing	/NAV	S JAPAN/NAV	DSTA
Patent Assignee (1)	/PA	S AMGEN/PA S KIRIN AMGEN/PA	CO
Publication Date (3)	/PD	S FEB 23, 1998/PD S 19980223/PD	PD, SO
Publication Year (3)	/PY	S PY>=1997	PY, SO
Reference (code and text)	/RE	S PINN/RE S BAN/RE	RE

Search and Display Field Codes (cont'd)

Search Field Name	Search Code	Search Examples	Display Codes
Revision Date (3)	/RDAT	S RDAT>=JAN 2001	RDAT
Revision Note	/RNTE	S 19980600/RDAT	RNTE
Source (contains journal title and publication date) (4)	/SO	S LICENS?/RNTE	SO
Stage (3)	/STG	S (R&D FOCUS AND 2001)/SO	DSTA, HDP
Status	/STA	S 20/STG	STA
Trade Name	/TN	S STG>30	CN, TN
Update Date (3)	/UP	S NEW DRUG/STA	UP
		S BETASERON/TN	
		S L7 AND UP>=20010100	

(1) Search with implied (S) proximity is available in this field.

(2) For details on the IMSRESEARCH Classification Codes, enter HELP CLASSCODES at an arrow prompt (=>) in the file.

(3) Numeric search field that may be searched with numeric operators or ranges.

(4) The source for all records is R&D Focus.

Limiting Search Codes

Only an L-number for an answer set created in DRUGUPDATES may be limited.

Search Field Name	Search Code	Search Examples
Available for licensing	/LICENSE	S L1/LIC,NEW (1,2)
New drugs	/NEW	S L1/NEW
Unavailable for licensing	/NLICENSE	S L1/NLI (1)

(1) The code may be abbreviated to the first three letters.

(2) An answer set may be limited to more than one subject area.

DISPLAY and PRINT Formats

Any combination of formats may be used to display or print answers. Multiple codes must be separated by spaces or commas, e.g., D L1 1-5 CN CO. The fields are displayed or printed in the order requested.

Hit-term highlighting is available in all fields except DSTA, CO, FA, GT, HDG, PY, STR, STS, and STF. Highlighting must be on during SEARCH to use the HIT, KWIC, and OCC display formats.

Format	Content	Examples
AN (1)	Accession Number	D L1 3 AN
CC	Classification Code	D CC 1,3-5
CT	Controlled Term (Indication and Pharmacology)	D CT
ED (UP)	Entry Date (Update Date)	D ED
FA (1,2)	Field Availability	D L1 FA 3
HDP (STG)	Highest Development Phase and Stage	D HDP
JT (1,2)	Journal Title	D 1,3,6,8 JT L5
LI	Latest Information	D LI
PD (1,2)	Publication Date	D L8 PD 1-3
PY (1,2)	Publication Year	D 1,4 PY
RDAT (RNTE)	Revision Date and Revision Note	D RDAT
RE (1)	Reference	D RE
RN	CAS Registry Number and CAS Registry Numbers for Derivatives	D L1 RN
SO (1)	Source	D SO

DISPLAY and PRINT Formats (cont'd)

Format	Content	Examples
STA (1) STF STR (3) STS (3) TN TX	Status Structure (No stereo bonds) Structure (Stereo bonds and R/S/E/Z labels, when available) Structure (Stereo bonds, when available) Trade Name Text (Patent Summary, Commercial Summary, Scientific Summary)	D STA L1 4 D STF 3,4 D STR D STS D L3 TN D TX 2 L5
ALL (3) CN CO DSTA (AV, NAV) GT IALL (3) IDE (3) IIDE (3) ISTD (3) PA (2) SCAN (1,4) STD (3) TRIAL (SAM) (1) CCTAB COTAB IDETAB	AN, SO, DN, STA, CN (Generic Name), RE, CN (Laboratory Name), CN (Trade Name), CN (Chemical Name) RN, STR, RN (Derivatives), CC, CT, HDP, ED, LI, DSTA, CO, TX, RDAT, RNTE Chemical Names (Generic Name, Reference, Laboratory Name, Trade Name, and Chemical Name) Tabular display of Company Information (Type, Company, Nationality, Corporation, Region) and Licensing Contact Tabular display of Development Status (Type, Status, Stage, Region, Indication) DSTA, CO ALL, indented with text labels AN, SO, STA, CN (Generic Name), RE, CN (Laboratory Name), CN (Trade Name), CN (Chemical Name), RN, STR, RN (Derivatives), CC, HDP, ED, CO (Default format) IDE, indented with text labels (IIDE is the default) STD, indented with text labels Tabular display of Patent Assignee information (Type, Company, Nationality, Corporation, Region) CN (Generic Name) (random display without answer number) AN, SO, STA, CN (Generic Name), RE, CN (Laboratory Name), CN (Trade Name), CN (Chemical Name), RN, STR, RN (Derivatives), CC, CT, HDP, ED, LI, DSTA, CO, TX CN (Generic Name) Table containing the answer number, Class, Compound (Generic Name), Highest Phase, and Originator for a single answer or several records in a single table Table containing the answer number, Company, Compound (Generic Name), Class, Highest Phase, and Type for a single answer or several records in a single table Table containing the answer number, RN, Compound (first Generic Name, first Laboratory Name, and first Trade Name), and Class for a single answer or several records in a single table	D ALL 2 D 1-3,7,8 CN D CO D DSTA D GT D IALL D IDE D L3 2 IIDE D ISTD D PA D L2 SCAN D STD D SAM 1-10 D L3 4-10 CCTAB D COTAB 1-10 D L4 IDETAB 1-3
HIT KWIC OCC (1)	Fields containing hit terms Hit terms plus 20 words on either side (KeyWord-In-Context) Number of occurrences of hit terms and fields in which they display	D HIT D KWIC D OCC 1-6

(1) No online display fee for this format.

(2) Custom display format only.

(3) Stereo structure diagrams are available only on graphics terminals and in offline prints.

(4) SCAN must be specified on the command line, i.e., D SCAN or DISPLAY SCAN.

SELECT, ANALYZE, and SORT Fields

The SELECT command is used to create E-numbers containing terms taken from the specified field in an answer set.

The ANALYZE command is used to create an L-number containing terms taken from the specified field in an answer set.

The SORT command is used to rearrange the search results in either alphabetic or numeric order of the specified field(s).

Field Name	Field Code	ANALYZE/ SELECT (1)	SORT
Accession Number	AN	Y	N
Availability for Licensing	AV	Y (3)	N
CAS Registry Number	RN	Y (4)	Y
CAS Registry Number and Chemical Names	CHEM	Y (5)	N
Chemical Name	CN	Y (6)	Y
	NAME	Y (7)	N
Classification Code	CC	Y	N
Company Name	CO	Y	Y
Controlled Term	CT	Y	N
Development Status	DSTA	Y (3,8)	N
Entry Date	ED	Y	Y
Geographic Term	GT	Y	N
Highest Development Phase	HDP	Y (3)	Y
Journal Title	JT	Y	Y
Latest Information	LI	Y (2)	N
Not Available for Licensing	NAV	Y (3)	N
Occurrence Count of Hit Terms	OCC	N	Y
Originator	ORIGINATOR	N	Y
Patent Assignee	PA	Y (3)	Y
Publication Date	PD	Y	Y
Publication Year	PY	Y (3)	Y
Revision Date	RDAT	Y	Y
Revision Note	RNTE	Y	N
Stage	STG	Y (3)	Y
Status	STA	Y	N
Trade Name	TN	Y	Y
Text	TX	Y (2)	N
Update Date	UP	Y	Y

- (1) HIT may be used to restrict terms extracted to terms that match the search expression used to create the answer set, e.g., SEL HIT CT.
- (2) Appends /BI to the terms created by SELECT.
- (3) SELECT HIT and ANALYZE HIT are not valid with this field.
- (4) Selects or analyzes the CAS Registry Numbers for the substance and any derivatives in the record with /BI appended to the terms created by SELECT.
- (5) Selects or analyzes the generic names, laboratory names, trades names, chemical name, and CAS Registry Numbers for the substance and any derivatives in the record with /BI appended to the terms created by SELECT.
- (6) Selects or analyzes the generic names, reference, laboratory names, trades names, and chemical name.
- (7) Selects or analyzes the generic names, laboratory names, trades names, and chemical name with /BI appended to the terms created by SELECT.
- (8) Selects or analyzes the status, region, and indication.

Sample Records

DISPLAY IALL

ACCESSION NUMBER: 2010:357 IMSRESEARCH
 SOURCE: R&D Focus, (04 Mar 2010)
 DOCUMENT NUMBER: 2500677
 STATUS: NEW DRUG
 LABORATORY NAME: ABT 072
 STRUCTURE:
 STRUCTURE DIAGRAM IS NOT AVAILABLE
 CLASSIFICATION: J5B1 Viral Hepatitis Products
 INDICATION: hepatitis C
 ACTION: RNA polymerase inhibitor
 ADMINISTRATION: oral
 HIGHEST DEV. PHASE: Phase II (40)
 ENTRY DATE: Entered STN: 8 Mar 2010
 Last Updated on STN: 6 Apr 2010
 LATEST INFORMATION: 04 March 2010 : Abbott and Enanta announced on 2 March 2010 the initiation of a phase II trial of ABT 450, ABT 333 and ABT 072 in treatment-naive patients with hepatitis C virus (HCV) genotype 1 infection. ABT 450, a protease inhibitor developed by Abbott and Enanta, and ABT 333 and ABT 072, two non-nucleoside polymerase inhibitors developed exclusively by Abbott, will be dosed individually in combination with standard of care (SOC). The study will evaluate the safety, tolerability, pharmacokinetics and antiviral activity of the agents. After a three-day monotherapy period, each antiviral agent will be administered with pegIFN and ribavirin (SOC) for 12 weeks, followed by SOC alone for an additional 36 weeks.

CURRENT DEVELOPMENT STATUS:

Type	Status	Stage	Region	Indication
Highest Phase	Phase II	40		
Phase				
Phase	Phase II	40	United States	hepatitis C

COMPANY INFORMATION:

Type	Company	Nationality	Corporation
Originator	Abbott	USA	Abbott (United States)

COMMERCIAL SUMMARY:

Commercial overview. Overview
 Abbott is developing ABT 072, a non-nucleoside polymerase inhibitor, for the treatment of hepatitis C virus (HCV) infection. A phase II trial of the agent initiated in February 2010 in patients with HCV genotype 1 infection.
 R&D progress. **Hepatitis C**
 Phase II, Abbott, USA.---DESIGN: Trial started - Feb 2010. A randomized, double-blind, parallel assignment phase II trial of ABT 450, ABT 333 and ABT 072 has been initiated in treatment-naive patients with hepatitis C virus (HCV) genotype 1 infection. The agents will be dosed individually in combination with standard of care (SOC). The study will evaluate the safety, tolerability, pharmacokinetics and antiviral activity of the agents. After a three-day monotherapy period, each antiviral agent will be administered with pegIFN and ribavirin (SOC) for 12 weeks, followed by SOC alone for an additional 36 weeks. The study's primary endpoint will be maximum decrease from baseline in log10 HCV RNA levels during treatment with the agents as monotherapy. Secondary endpoints include the assessment of patients with RVR (HCV RNA level less than 25 IU/mL), as well as partial EVR (HCV RNA decrease more than 2 log10 IU/mL) or complete EVR (HCV RNA level less than 25 IU/mL) (Abbott, MAR 2010; ClinicalTrials.gov, FEB 2010).
 Phase I, Abbott, USA.---DESIGN: Trial started - Sep 2009. A randomized, placebo-controlled phase I trial of single and multiple doses of ABT 072 has been conducted in the USA in approximately 52 healthy volunteers (ClinicalTrials.gov, FEB 2010).
 Phase I, Abbott, USA.---DESIGN: Trial started - Jul 2009. An open-label, randomized phase I trial has been conducted to evaluate the bioavailability of two ABT 072 tablet formulations compared with ABT 072 capsule formulation in approximately 18 healthy volunteers (ClinicalTrials.gov, AUG 2009).
 Phase I, Abbott, USA.---DESIGN: Trial started - Apr 2009. A randomized, double-blind phase I trial of ABT 072 has been conducted in approximately 32 healthy volunteers. Safety, tolerability and pharmacokinetics of multiple doses of ABT 072 have been assessed (ClinicalTrials.gov, JUL 2009).
 Phase I, Abbott, USA.---DESIGN: Trial started - Sep 2008. A randomized, double-blind phase I trial to evaluate the safety, tolerability and

pharmacokinetics of ABT 072 has been conducted in approximately 100 healthy volunteers and HCV genotype 1 infected patients (ClinicalTrials.gov, MAY 2009).

DEVELOPMENT HISTORY:

FEB 2010 Abbott trial started (Phase II), USA (hepatitis C) .
SEP 2008 Abbott trial started (Phase I), USA (hepatitis C) .

D IIDE

ACCESSION NUMBER: 2010:517 IMSRESEARCH
SOURCE: R&D Focus, (08 Apr 2010)
DOCUMENT NUMBER: 2500831
STATUS: NEW DRUG
GENERIC NAME: tuberculosis therapy, MicuRx/Cumencor/Pfizer
STRUCTURE:

STRUCTURE DIAGRAM IS NOT AVAILABLE

CLASSIFICATION: J4A Antitubercular Products
HIGHEST DEV. PHASE: Discovery (10)
ENTRY DATE: Entered STN: 9 Apr 2010
Last Updated on STN: 9 Apr 2010

COMPANY INFORMATION:

Type	Company	Nationality	Corporation
Originator	Cumencor	China	Cumencor (China)
Originator	MicuRx	USA	MicuRx (United States)
Originator	Pfizer	USA	Pfizer (United States)

In North America

CAS Customer Center
P.O. Box 3012
Columbus, Ohio 43210-0012
U.S.A.

Phone: 800-753-4227 (North America)
614-447-3731 (worldwide)
Email: help@cas.org
Internet: www.cas.org

In EMEA

CAS Customer Center EMEA
(represented by FIZ Karlsruhe)
P.O. Box 2465
76012 Karlsruhe
Germany

Phone: +49-7247-808-555
E-mail: EMEAhelp@cas.org

In Japan

JAICI (Japan Association for
International Chemical Information)
Nakai Building
6-25-4 Honkomagome, Bunkyo-ku
Tokyo 113-0021
Japan

Phone: +81-3-5978-3601 (Technical Service)
+81-3-5978-3621 (Customer Service)
Email: support@jaici.or.jp (Technical Service)
customer@jaici.or.jp (Customer Service)
Internet: www.jaici.or.jp